{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:56:03Z","timestamp":1767855363526,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T00:00:00Z","timestamp":1723334400000},"content-version":"am","delay-in-days":315,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.pupt.2023.102248","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T21:32:54Z","timestamp":1691530374000},"page":"102248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Effects of elexacaftor-tezacaftor-ivacaftor on daily treatment burden and airflow obstruction in adults with cystic fibrosis"],"prefix":"10.1016","volume":"82","author":[{"given":"Angelica","family":"Tiotiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iulia","family":"Ioan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Billon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2023.102248_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03079-2020","article-title":"Efficacy of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease","volume":"57","author":"O'Shea","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2023.102248_bib2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2023.102248_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2023.102248_bib4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2023.102248_bib5","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2023.102248_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2023.102248_bib7","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jcf.2022.05.005","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis","volume":"21","author":"Song","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2023.102248_bib9","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2023.102248_bib10","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2023.102248_bib11","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1378\/chest.94.4.799","article-title":"The shape of the maximum expiratory flow volume curve","volume":"94","author":"Kapp","year":"1988","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2023.102248_bib12","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ppul.22518","article-title":"Quantification of shape of flow-volume loop of healthy preschool children and preschool children with wheezing disorders","volume":"47","author":"N\u00e8ve","year":"2012","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.pupt.2023.102248_bib13","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1513\/AnnalsATS.201511-774OC","article-title":"Subjective and objective assessments of flow-volume curve configuration in children and young adults","volume":"13","author":"Weiner","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.pupt.2023.102248_bib14","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1164\/ajrccm\/151.3_Pt_2.S70","article-title":"Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis","volume":"151","author":"Hodson","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2023.102248_bib15","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00003495-200767070-00002","article-title":"Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?","volume":"67","author":"King","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.pupt.2023.102248_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0954-6111(95)90249-X","article-title":"The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis","volume":"89","author":"van Haren","year":"1995","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2023.102248_bib17","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jcf.2022.03.002","article-title":"Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis","volume":"21","author":"Stapleton","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2023.102248_bib18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jcf.2022.06.003","article-title":"Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis","volume":"21","author":"Shakir","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2023.102248_bib19","first-page":"CD001912","article-title":"Prophylactic anti-staphylococcal antibiotics for cystic fibrosis","volume":"9","author":"Rosenfeld","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pupt.2023.102248_bib20","article-title":"Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease","volume":"80","author":"Martin","year":"2021","journal-title":"Respir Med Res"},{"key":"10.1016\/j.pupt.2023.102248_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2023.102248_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2022.110421","article-title":"Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: early report","volume":"154","author":"Bec","year":"2022","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.pupt.2023.102248_bib23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcf.2021.03.016","article-title":"Peripheral lung effect of elexacaftor\/tezacaftor\/ivacaftor in adult cystic fibrosis","volume":"21","author":"Stylemans","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2023.102248_bib24","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1513\/AnnalsATS.201511-774OC","article-title":"Subjective and objective assessments of flow-volume curve configuration in children and young adults","volume":"13","author":"Weiner","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.pupt.2023.102248_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000194568","article-title":"Cystic fibrosis related lung diseases in young adults with minimal impairment","volume":"44","author":"Guidotti","year":"1983","journal-title":"Respiration"},{"key":"10.1016\/j.pupt.2023.102248_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.resp.2021.103722","article-title":"Lung inflammation and simulated airway resistance in infants with cystic fibrosis","volume":"293","author":"DeBoer","year":"2021","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.pupt.2023.102248_bib27","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1513\/AnnalsATS.202102-220RL","article-title":"Efficacy of elexacaftor\/tezacaftor\/ivacaftor in advanced cystic fibrosis lung disease","volume":"18","author":"Djavid","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.pupt.2023.102248_bib28","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/17476348.2021.1951707","article-title":"Impact of the COVID-19 pandemic on the management of chronic noninfectious respiratory diseases","volume":"15","author":"Tiotiu","year":"2021","journal-title":"Expet Rev. Respir. Med."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:31:53Z","timestamp":1761082313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553923000603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":27,"alternative-id":["S1094553923000603"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102248","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of elexacaftor-tezacaftor-ivacaftor on daily treatment burden and airflow obstruction in adults with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102248"}}